Ovid Therapeutics Reports Tomorrow With One Clinical Milestone Cleared and Another Still Unproven

Ovid Therapeutics (NASDAQ: OVID) reports Q1 2026 earnings on May 12, 2026, before market open, with analysts expecting a loss of $-0.12 per share. The clinical-stage biopharmaceutical company faces a pivotal moment as investors assess progress on its pipeline of therapies for rare neurological disorders, particularly following the regulatory clearance of its first-ever oral KCC2 direct activator and the expansion of its OV329 program into new indications. With the stock trading above all major moving averages and a maximum-strength buy signal, the question is whether the company's recent clinical milestones and capital raise can sustain momentum or whether execution risks will weigh on sentiment.

Part 1: Earnings Preview

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for rare neurological disorders, with a pipeline centered on small-molecule modulators targeting neural hyperexcitability. The company's lead programs include OV329, a next-generation GABA aminotransferase inhibitor for epilepsy, and OV4071, the first oral KCC2 direct activator for CNS disorders.

Ovid is scheduled to report Q1 2026 earnings on May 12, 2026, before market open, with a conference call at 9:30 AM ET. Analysts expect a loss of $-0.12 per share on revenue of $0.06 million. The most recently reported quarter (Q4 2025) delivered actual EPS of $0.06, a significant beat versus the $-0.10 estimate. Compared to the same quarter last year (Q1 2025), when the company reported $-0.14 per share, the current estimate of $-0.12 represents a 14.29% improvement year-over-year.

Three key themes define this earnings story:

Pipeline Advancement and Regulatory Progress: The March 2026 announcement of regulatory clearance for OV4071 in Australia—a quarter ahead of schedule—marks a critical milestone as the first-ever oral KCC2 direct activator to reach clinical trials. Investors will scrutinize updates on the Phase I study initiation and the ketamine challenge planned for 2026, as well as progress on OV329's Phase II randomized trial for focal onset seizures expected to start in Q2 2026. The company's ability to execute on multiple clinical catalysts through 2027 will be central to maintaining confidence in the development timeline.

Expansion into Pediatric Rare Epilepsies: Ovid's decision to expand OV329 into infantile spasms and tuberous sclerosis complex (TSC) seizures represents a strategic pivot that could significantly broaden the commercial opportunity. The 7 mg dose data showed no treatment-related serious adverse events and no ophthalmic safety signals, which management believes materially de-risks the program. Investors will want clarity on the design and timelines for these signal-finding studies, as well as how the company plans to develop weight-based pediatric formulations and potentially pursue combined pivotal pathways.

Capital Position and Runway Extension: The $60 million PIPE financing led by Point72, combined with the potential exercise of Series A warrants that could add more than $53 million, positions Ovid with a cash runway extending well into 2029 according to management. This financial cushion is critical for advancing multiple programs simultaneously without compromising existing development plans. Investors will assess whether the company's burn rate aligns with stated projections and how efficiently capital is being deployed across the expanded pipeline.

Analysts remain overwhelmingly bullish heading into the release, with 11 of 12 analysts rating the stock a Strong Buy and a mean price target of $4.93 implying 76% upside. The consensus view emphasizes the de-risking achieved through the OV329 safety data and the strategic value of the KCC2 platform, though some caution that execution on multiple concurrent programs will be essential to justify the valuation.

Part 2: Historical Earnings Performance

Ovid Therapeutics has demonstrated a mixed but recently improving earnings track record over the past four quarters. In Q1 2025, the company reported $-0.14 per share, exactly matching the consensus estimate. Q2 2025 delivered a significant positive surprise, with actual EPS of $-0.06 beating the $-0.16 estimate by 62.50%. Q3 2025 saw a modest miss, with $-0.17 reported versus $-0.15 estimated, representing a -13.33% surprise. Most notably, Q4 2025 produced a dramatic beat with actual EPS of $0.06 versus the $-0.10 estimate, a 160.00% positive surprise that marked the company's first profitable quarter in recent history.

The pattern reveals increasing volatility in earnings outcomes, with the magnitude of surprises—both positive and negative—growing over time. The Q4 2025 result stands out as an outlier, likely driven by one-time factors rather than sustainable profitability given the company's clinical-stage status. The two substantial beats in Q2 and Q4 2025 suggest that when Ovid outperforms, it tends to do so meaningfully, potentially reflecting better-than-expected expense management or revenue recognition timing. However, the Q3 miss indicates that execution remains uneven, and investors should not assume the Q4 profitability will repeat in Q1 2026 given the consensus estimate of $-0.12.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Ovid Therapeutics typically reports earnings before market open, meaning Day 0 represents the first full trading session where the market reacts to results, while Day +1 captures follow-through momentum.

Historical price behavior around earnings shows significant volatility, with an average absolute Day 0 move of 12.33% and Day 0 range of 17.16%. The most dramatic reaction came on August 13, 2025, when the stock surged 56.86% on Day 0 following a strong earnings beat, though it gave back 2.06% the following session. The March 18, 2026 report (Q4 2025) produced a 14.43% Day 0 gain, consistent with the positive earnings surprise. Day +1 moves have been more modest, averaging 4.46%, suggesting that initial reactions tend to hold rather than reverse sharply. The wide Day 0 ranges—often exceeding 10%—indicate that OVID experiences substantial intraday volatility during earnings sessions, creating both opportunity and risk for traders. Investors should anticipate a double-digit percentage move in either direction based on whether the company beats or misses estimates and, critically, on the quality of pipeline updates and guidance provided on the conference call.

Part 2.2: Options Market Expected Move

The options market is pricing in an expected move of 10.36% for the May 15, 2026 expiration, which is notably lower than the 12.33% average absolute Day 0 move observed historically. This suggests the options market may be underpricing potential volatility, particularly given OVID's recent pattern of delivering significant surprises—both the 62.50% Q2 2025 beat and the 160.00% Q4 2025 beat resulted in moves exceeding the current implied move. Traders positioning for earnings may find value in long volatility strategies if they believe the historical pattern of outsized reactions will continue.

Part 3: What Analysts Are Saying

Analyst sentiment on Ovid Therapeutics is overwhelmingly bullish, with 11 of 12 analysts rating the stock a Strong Buy, one Hold, and zero Sell ratings. The average recommendation of 4.83 on a 5-point scale reflects near-maximum conviction. The mean price target of $4.93 implies 76% upside from the current price of $2.80, with a high estimate of $7.00 (150% upside) and a low estimate of $2.40 (14% downside). This wide range reflects differing views on the probability and timeline for clinical and commercial success, though even the most conservative target suggests modest upside.

Analyst sentiment has remained unchanged over the past month, with the Strong Buy count holding steady at 11 and the average recommendation unchanged at 4.83. This stability suggests analysts are maintaining their bullish stance following the March 2026 pipeline updates and capital raise, rather than rushing to upgrade after the news. The consensus appears to reflect confidence in the company's expanded development strategy and extended cash runway, with the KCC2 platform and OV329's safety profile cited as key differentiators. However, the lack of recent upgrades also indicates that much of the positive news may already be reflected in current ratings, and analysts may be waiting for additional clinical data or execution milestones before increasing conviction further.

Part 4: Technical Picture

Ovid Therapeutics enters earnings with a maximum-strength technical setup, as the Barchart Technical Opinion shows a 100% Buy signal that has remained unchanged over the past week and month. The stock is trading at $2.80, positioned above all major moving averages: the 5-day ($2.79), 10-day ($2.78), 20-day ($2.78), 50-day ($2.45), 100-day ($2.03), and 200-day ($1.66). This alignment indicates a strong uptrend across all timeframes, with the stock having gained substantial ground from its longer-term averages—68.7% above the 200-day moving average.

Timeframe Analysis:

• Short-term (100% Buy): Maximum buy signal indicates powerful near-term momentum heading into the earnings release
• Medium-term (100% Buy): Sustained strength in the intermediate timeframe suggests the uptrend is well-established rather than a short-term spike
• Long-term (100% Buy): Strong long-term buy signal reflects a fundamental shift in the stock's trajectory, likely driven by the pipeline progress and capital raise announced in March 2026

Trend Characteristics: The maximum-strength signal combined with a strengthening direction suggests OVID is in a robust uptrend with building momentum, creating a technically supportive environment for earnings but also raising the bar for positive surprises to drive further gains.

The technical picture is decidedly bullish, with the stock trading well above all moving averages and showing no signs of resistance from overhead technical levels. The 50-day moving average at $2.45 has provided strong support, and the stock's ability to hold above the shorter-term averages ($2.78-$2.79) suggests consolidation at elevated levels rather than exhaustion. However, the maximum buy signal and extended position above longer-term averages also mean the stock has less room for disappointment—any earnings miss or cautious guidance could trigger profit-taking. The strengthening trend direction indicates momentum remains positive, but investors should be aware that much good news appears already priced in, making execution on clinical milestones and pipeline updates critical to sustaining the rally beyond earnings.